netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 Formulary Chapter 7: Obstetrics, Gynaecology, and urinary-tract disorders - Full Chapter

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

07.04.05  Expand sub section  Drugs for erectile dysfunction

For managing erectile dysfunction associated with prostate cancer treatment, refer to NICE Guideline NG131

07.04.05  Expand sub section  Alprostadil
Alprostadil intracavernosal injection (Viridal®, Caverject®)
View adult BNF View SPC online
Second Choice
Amber 2

Alprostadil transurethral application (MUSE® urethral sticks, Vitaros® topical cream)
View adult BNF View SPC online
Second Choice
Amber 2

Link  SEL IMOC Recommendation: Alprostadil 3mg/g cream (Vitaros™) for the management of erectile dysfunction in adult males
07.04.05  Expand sub section  Phosphodiesterase type 5 inhibitors
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

Amber 1

Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

Amber 2

Specialist initiation followed by maintenance prescribing in primary care  

Amber 3

Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  


Specialist and non-specialist initiation  


Not recommended for prescribing